Clinical Trials
107 trialsLisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
The Affiliated People's Hospital of Ningbo University
HematoCare
Azienda USL Reggio Emilia - IRCCS
OHGW-ACP
Azienda USL Reggio Emilia - IRCCS
KRWS
Korea Institute of Radiological & Medical Sciences
TITLE CLL
The Royal Wolverhampton Hospitals NHS Trust
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
Sheba Medical Center
ETCABIO
University Hospital, Angers
CELESTIAL-MDS
Clinical Hub for Interventional Research (CHOIR)
HematoBrain
University Hospital, Angers
ACL ALL
ASL Lecce
CARE-RT
Jinnah Postgraduate Medical Centre
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
Sheba Medical Center
COSMOS-Avatar
Clinical Hub for Interventional Research (CHOIR)
EPOCH
Hospital General de Mexico
TREATT
NHS Blood and Transplant
ALHERT
University Hospital, Angers
EscrimHEMA
University Hospital, Angers
MMYLIFE
Azienda USL Reggio Emilia - IRCCS
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Anhui Provincial Hospital
ED2024
Azienda USL Reggio Emilia - IRCCS
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Anhui Provincial Hospital
EPC-EMA1
Azienda USL Reggio Emilia - IRCCS
ETAF
Azienda USL Reggio Emilia - IRCCS
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
SCTMICROBIOM
National Cancer Institute, Slovakia
ECAR01
Anhui Provincial Hospital
PALERMO
University Hospital, Angers
Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia
National Institute of Pediatrics, Mexico
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
The Third Affiliated Hospital of Southern Medical University
SCRIPT-AML
Vastra Gotaland Region
CANSI
Turku University Hospital
RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies
Henan Cancer Hospital
RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL
Anhui Provincial Hospital
SHACK
KK Women's and Children's Hospital
BIG-1
University Hospital, Angers
Shoulder Instability in Children: Muscle Activity and Movement
Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases
Anhui Provincial Hospital
Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
Kirby Institute
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Anhui Provincial Hospital
RAT-HEMATO
University Hospital, Angers
The Maintenance Treatment of "ITIVA" in AML Patients
Henan Cancer Hospital
CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression
Sheba Medical Center
Bisantrene Combination for Resistant AML
Sheba Medical Center
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Anhui Provincial Hospital
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia.
Coordinación de Investigación en Salud, Mexico
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
KK Women's and Children's Hospital
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
KK Women's and Children's Hospital